The Challenges of Hepatitis B Clinical Care Within Underserved Communities
October 30th 2024In the second part of their interview, Debika Bhattacharya, MD MSc, and Su H. Wang, MD, MPH, FACP, continue the conversation around the difficulties of getting people into care, and what the new hepatitis B guidelines hope to improve in this area.
Read More
Targeted Prophylaxis Reduces Hospital-Onset C difficile Infections in High-Risk Patients
October 22nd 2024The STOP-CDI intervention presented by Matthew J.Ziegler, MD MSCE revealed using prophylactic enteral vancomycin, significantly reduced hospital-onset C difficile infections among immunocompromised patients.
Read More
Evaluating the Efficacy of Paxlovid in High-Risk Patients with Pre-Existing Immunity
October 22nd 2024John McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.
Read More
A Monoclonal Antibodies' Prospective Place in the COVID-19 PrEP Market
October 21st 2024Invivyd’s Chief Scientific Officer Robert Allen, PhD, discusses the company’s pemivibart (Pemgarda) including its administration, how it can be used in concert with vaccines, and how it protects against newer variants.
Read More
Long-Acting Injectable HIV Therapy: Addressing Adherence Challenges
October 21st 2024Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.
Read More
Getting Patients Involved in C diff Advocacy, Treatment Guidelines
October 18th 2024Peggy Lillis Foundation CEO Christian Lillis believes patients need a seat at the table so he is advocating for past patients to become ambassadors to be a voice to help shape treatment and also continue to raise awareness about the infection.
Read More
First-Hand Insights into Treating Hepatitis C in Pregnancy
October 17th 2024Catherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.
Read More
Analyzing Household Transmission of COVID-19
October 17th 2024At ID Week 2024, an investigator, Amanda M. Casto, MD, PhD, discusses her work on the CASCADIA study, which examined infection rates in this setting, and how it challenged assumptions that there is likely a singular carrier bringing viruses into homes.
Read More
Enhancing Outcomes in Outpatient Parenteral Antimicrobial Therapy
October 17th 2024Nabin K. Shrestha, MD, MPH, evaluates the Cleveland Clinic's Outpatient Parenteral Antimicrobial Therapy (OPAT) program, revealing its effectiveness in managing infections while highlighting challenges in monitoring and the impact of infectious disease pharmacists on patient outcomes.
Read More
Kalihinol Analog Targets Apicoplast Function In Malaria Treatment
October 17th 2024Karine G. Le Roch, PhD, discussed her research on a kalihinol analog that combats drug resistance in malaria, emphasizing the need for innovative treatments in the context of climate change and rising transmission rates.
Read More
Investigational Antibiotic Shows Efficacy, Safety in Late Stage Trial for Uncomplicated Gonorrhea
October 16th 2024A phase 3 therapy, zoliflodacin, has shown to be noninferior in a late stage trial. The therapy's manufacturer, Innoviva Speciality Therapeutics, is presenting data at this week's ID Week. The company's CMO David Altarac, MD, offers some insights on the therapy and the timeline for filing the paperwork for prospective FDA approval.
Read More
Gilead's Phase 1a Trial Results Indicate GS-1720 as a Potential Long-Acting HIV Treatment
October 16th 2024GS-1720 could offer a weekly dosing option for individuals living with HIV, supported by a good safety profile with no serious adverse events, which has led to the initiation of a Phase 2 study.
Read More